-
Mashup Score: 2FDA Advisory Panel Calls for Randomized Data for PI3K Inhibitor Approvals for Blood Cancers - 2 year(s) ago
An FDA Oncologic Drugs Advisory Committee (ODAC), meeting on April 21, voted almost unanimously to recommend that drug companies conduct randomized clinical trials before seeking the approval of PI3K inhibitors, based on concerns over patient survival data and significant toxicities. The class of cancer drugs are currently indicated for hematologic malignancies including Chronic Lymphocytic…
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4KRAS G12C Inhibitor Sotorasib May Offer Long-term Clinical Benefit in Patients with Non-small Cell Lung Cancer - 2 year(s) ago
(AACR) Apr 10, 2022 – Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#AACR22 Encouraging 2 year survival of 32% with KRAS G12C inhibitor Sotorasib in Patients with Non-small Cell Lung Cancer https://t.co/xH2l0M6q2n #OBRoncology via @OBRTweets
-
-
Mashup Score: 0
(Merck) Mar 15, 2022 – Merck, known as MSD outside the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after treatment with chemotherapy and either…
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Another example of failure of PARP inhibitor therapy when no enrichment strategy: KEYLYNK-010 Trial Of pembrolizumab Combine#d with olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility https://t.co/MaH9RgaCfB #OBRoncology via @OBRTweets
-
-
Mashup Score: 2Aromatase Inhibitors Are Better Than Tamoxifen At Reducing The Risk Of Breast Cancer Recurrence In Premenopausal As Well As Postmenopausal Women - 2 year(s) ago
(University of Oxford [UK]) Feb 3, 2022 – A new study led by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) based at Oxford Population Health has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with oestrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of breast cancer recurrence. The results have been…
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
ICYMI: Aromatase inhibitors > tamoxifen in premenopausal as well as postmenopausal women. @UTSWIMchief @utswcancer @UTSWInternalMed @TimothyJBrownMD @timilpatel @guptaarjun90 @alaccetti @heatherwolfe @trile1988 @DinoKazi https://t.co/HYFMV0WAB5 #OBRoncology via @OBRTweets
-
-
Mashup Score: 14
(BeiGene) Jan 24, 2022 – BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced positive findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with locally…
Source: www.obroncology.comCategories: Latest Headlines, Oncologists1Tweet-
BeiGene Announces Positive Findings from Phase 3 (RATIONALE-305) Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer https://t.co/MhRUFsobJh #OBRoncology via @OBRTweets
-
-
Mashup Score: 5
Lajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.
Source: www.obroncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Chair of the @SWOG breast committee Dr. Lajos Pusztai discusses results reported at #SABCS21 from KEYNOTE-522 and RxPONDER #breastcancer trials. #bcsm @YaleCancer @KalinskyKevin Neoadjuvant I-O and Oncotype DX https://t.co/gyEt8pFkyL #OBRoncology via @OBRTweets
-
-
Mashup Score: 1
(Merck) Jan 10, 2022 – Merck, known as MSD outside the United States and Canada, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Thoracic Oncology Platform (ETOP) today announced that the Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of…
Source: www.obroncology.comCategories: Latest Headlines, Oncologists1Tweet-
The 2nd “domino to fall” in adjuvant IO for early stage NSCLC:Pembrolizunab shows statistically Significant Improvement in DFS Vs Placebo as Adjuvant Treatment for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression https://t.co/oO62WowsNx #OBRoncology via @OBRTweets
-
-
Mashup Score: 0
(MD Anderson) Jan 5, 2022 – In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile, according to the results of the Phase II/III RELATIVITY-047 clinical trial reported by The University of Texas MD Anderson Cancer Center…
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Relatlimab Plus Nivolumab Improves Progression-Free Survival In Metastatic Melanoma https://t.co/TsfMbppZ9O #OBRoncology via @OBRTweets
-
-
Mashup Score: 1Acute Myeloid Leukemia Highlights at ASH 2021 - 2 year(s) ago
Mikkael Sekeres, MD, discusses his ASH acute myeloid leukemia highlights, including studies on combination therapies, treating older adults, and end-of-life care.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Acute Myeloid Leukemia Highlights at #ASH21 with @MikkaelSekeres #leusm https://t.co/shB4l9A2M0 #OBRoncology via @OBRTweets
-
-
Mashup Score: 0Mirati Gives First Look At KRAS Drug Combination In Lung Cancer - 3 year(s) ago
(BioPharma Dive) Nov 8, 2021 – Mirati Therapeutics on Monday offered a limited glimpse at the first trial results for a combination of its experimental KRAS-blocking drug and Merck & Co.’s Keytruda, giving a much-anticipated update as the San Diego-based biotech attempts to convince investors its treatment can challenge Amgen’s rival medicine Lumakras.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Mirati Gives First Look At KRAS Drug Combination In Lung Cancer https://t.co/BAy8u4VEhX #OBRoncology via @OBRTweets @Mirati 🧬 @kRasKickers #lcsm
-
ICYMI: ODAC wants RCTs for PI3K inhibitors. The challenge of surrogate endpoints. @utswcancer @UTSWHemeOnc @TimothyJBrownMD @guptaarjun90 @JasmineSukumar @JVentoMD @rmelias2 @trile1988 @alaccetti @timilpatel https://t.co/b9fyWoEsK9 #OBRoncology via @OBRTweets